KPV Peptide: Anti-Inflammatory and Gut Health Research 2026

What is KPV?

KPV is a synthetic tripeptide composed of lysine, proline, and valine (Lys-Pro-Val) — corresponding to the C-terminal three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). With a molecular weight of only 340.4 Da, KPV is among the smallest research peptides in the regenerative and anti-inflammatory categories. Despite its small size, the compound has a mechanistically distinctive profile: it retains anti-inflammatory activity even in melanocortin-receptor-knockout preclinical models, indicating a receptor-independent mechanism. Researchers can access KPV research peptide from Advanced Peptide Science at 99%+ HPLC-verified purity.

Research Background

KPV emerged from research dissecting which portions of alpha-melanocyte-stimulating hormone (alpha-MSH) are responsible for its various biological activities. Native alpha-MSH is a 13-residue peptide with broad pharmacological effects across the melanocortin receptor family (MC1R, MC3R, MC4R, MC5R) plus receptor-independent anti-inflammatory effects. Structure-activity research identified the C-terminal Lys-Pro-Val tripeptide as carrying the receptor-independent anti-inflammatory activity, distinct from the central receptor-binding region. Compare against the larger Melanotan II (cyclic alpha-MSH analogue, MC1R/MC4R agonist) for receptor-mediated vs receptor-independent mechanism research.

Mechanism of Action

Mechanism research investigates KPV’s direct intracellular modulation of NF-kappaB signalling — likely via inhibition of IKK (IκB kinase) mediated phosphorylation cascades. The result is reduced NF-kappaB nuclear translocation and consequent reduction in pro-inflammatory cytokine transcription. The receptor-independent mechanism is unusual for a peptide of this small size — the standard assumption would be membrane receptor binding, but KPV appears to act on intracellular signalling pathways directly. Additional research investigates effects on tight junction protein expression and intestinal epithelial barrier function, plus interaction with melanocortin-pathway-independent inflammation regulators.

Key Research Findings

Receptor-Independent Anti-Inflammatory Activity

The defining mechanistic feature of KPV is anti-inflammatory activity that persists in melanocortin-receptor-knockout preclinical models. This receptor independence distinguishes KPV from larger alpha-MSH fragments and is a research-tool advantage for dissecting receptor-mediated vs receptor-independent components of alpha-MSH biology.

NF-kappaB Pathway Modulation

NF-kappaB is a master transcriptional regulator of pro-inflammatory gene expression. KPV research investigates inhibition of IKK-mediated IκB phosphorylation, with downstream reduction in NF-kappaB nuclear translocation and pro-inflammatory cytokine production. The mechanism is investigated at the protein-protein interaction level rather than via a defined membrane receptor.

Intestinal Epithelial Barrier Research

A major research application area for KPV is investigation of intestinal epithelial barrier function. Research focuses on tight junction protein expression (occludin, claudin family, ZO-1), epithelial cell viability, and gut-barrier integrity in preclinical IBD and intestinal inflammation models. The receptor-independent anti-inflammatory profile is particularly well-suited to this research area where receptor distribution heterogeneity across intestinal cell types would otherwise confound interpretation.

Research Applications and the KLOW Blend

KPV is most prominently featured in the KLOW Blend — a four-compound research formulation combining KPV with BPC-157, TB-500, and GHK-Cu. The blend enables multi-pathway research at the intersection of regenerative biology, anti-inflammatory signalling, and extracellular matrix remodelling. The Tissue Repair & Regenerative category additionally stocks ARA-290 for innate-repair-receptor research and the other foundational regenerative compounds.

Research Specifications

Molecular Weight	340.4 Da
Sequence	Lys-Pro-Val (KPV) — C-terminal tripeptide of alpha-MSH
Mechanism Class	Receptor-independent anti-inflammatory (NF-kappaB modulation)
Format	Lyophilized powder in sterile vial
Purity	≥ 99% (HPLC verified)
Storage	-20 °C, protect from light

Frequently Asked Questions

What is unusual about KPV’s mechanism?

KPV exhibits anti-inflammatory activity that persists in melanocortin-receptor-knockout preclinical models — indicating a receptor-independent mechanism unusual for a peptide of any size. The compound modulates NF-kappaB signalling directly rather than via a defined membrane receptor.

How does KPV differ from Melanotan II?

Melanotan II is a cyclic lactam alpha-MSH analogue that acts via melanocortin receptor agonism (MC1R, MC4R). KPV is the C-terminal tripeptide of alpha-MSH that acts via receptor-independent NF-kappaB pathway modulation. The two compounds engage different alpha-MSH biology branches.

Where can researchers source KPV?

KPV research peptide is available at Advanced Peptide Science at 99%+ HPLC-verified purity, plus as a component of the KLOW Blend.

Is KPV approved for human use?

Advanced Peptide Science supplies KPV exclusively for in vitro and in vivo scientific research. Not for human consumption. Research use only.

---

For Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.